Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy male and/or female subjects
Between the ages of 18 and 55 years, inclusive
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs)
You may not be if
Elevated risk of suicide, in the opinion of the investigator or expert consultant
Pregnant or nursing females
Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception
Clareo Health | Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet
